Kyverna says small group of rare disease patients all responded to its CAR-Tnews2025-10-29T14:44:27+00:00October 29th, 2025|Endpoints News|
GSK trims pipeline, bumps guidance in Emma Walmsley’s last earnings reportnews2025-10-29T11:34:00+00:00October 29th, 2025|Endpoints News|
BridgeBio gets another Phase 3 rare disease win, this time in thyroid disordernews2025-10-29T11:00:39+00:00October 29th, 2025|Endpoints News|
DNA-chopping enzyme that breaks up NETs may offer new way to fight autoimmune disease, early data from Neutrolis suggestnews2025-10-29T10:00:58+00:00October 29th, 2025|Endpoints News|
FDA clears at-home use for Delix’s next neuroplastogen studynews2025-10-28T19:22:46+00:00October 28th, 2025|Endpoints News|
Cigna says it will end drug rebates as pressure mounts on PBMsnews2025-10-27T18:47:43+00:00October 27th, 2025|Endpoints News|
Cigna says it will end drug rebates as pressure mounts on PBMsnews2025-10-27T18:47:43+00:00October 27th, 2025|Endpoints News|
Intellia pauses two CRISPR trials after liver toxicity hospitalizes patientnews2025-10-27T16:48:44+00:00October 27th, 2025|Endpoints News|
Intellia pauses two CRISPR trials after liver toxicity hospitalizes patientnews2025-10-27T16:48:44+00:00October 27th, 2025|Endpoints News|
Zenas’ multiple sclerosis drug slows new brain lesions in mid-stage trialnews2025-10-27T15:00:40+00:00October 27th, 2025|Endpoints News|
